Zotiraciclib
Rectal Cancer
Targovax ASASmall moleculePhase 1Dormant
C
36/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 24/ 100
- Competitive Position
- 73/ 100
Competitive context
114 Active assets in the Rectal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Fudan University | Phase 2 | BBB |
Capecitabine Gustave Roussy, Cancer Campus, Grand Paris | Phase 4 | BBB |
Eloxatin Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 | BBB |
Floxuridine City of Hope Medical Center | Phase 2 | BBB |
FLUOROURACILUM Gustave Roussy, Cancer Campus, Grand Paris | Phase 3 | BBB |
View all 50 →
Same molecule, other indications
Zotiraciclib is also rated in:
blast phase chronic myelogenous leukemia, BCR-ABL1 positiveDormant
CC
Indicative ·
41 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →